The benefits are endless.It is worth mentioning that among the stocks with a market value of less than 10 billion yuan, Kaikai Industry, Fudan Fuhua, First Hospital and Xuantai Medicine all belong to the biomedical industry. Among the state-owned shares in Shanghai, Hua Hong Company and Hehui Optoelectronics -U belong to the semiconductor industry.From the perspective of institutional attention, Zhongwei Company and Weir Co., Ltd. have more than 30 institutional ratings, while Hengxuan Technology, Lanqi Technology, UIH Medical and Microelectrophysiology -U have more than 20 institutional ratings.
[The time is ripe for Shanghai stocks to become monsters in batches! 】According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.
[The time is ripe for Shanghai stocks to become monsters in batches! 】Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14